Sanofi: successful Apollo study on Patisiran.
(CercleFinance.com) - Sanofi Genzyme and Alnylam have announced that the APOLLO Phase 3 trial of patisiran, an experimental RNAi therapeutic agent, has met its primary endpoint and all of its secondary endpoints.
The APOLLO trial recruited 225 patients with hereditary ATTR amyloidosis with polyneuropathy from 44 study sites in 19 different countries.
Patisiran achieved a highly significant reduction in neuropathy progression and improvement in quality of life at 18 months compared to placebo.
Alnylam intends to submit a New Drug Application (NDA) at the end of 2017 and a marketing authorization application in early 2018. The full results of the study will be presented at a European Congress in November.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The APOLLO trial recruited 225 patients with hereditary ATTR amyloidosis with polyneuropathy from 44 study sites in 19 different countries.
Patisiran achieved a highly significant reduction in neuropathy progression and improvement in quality of life at 18 months compared to placebo.
Alnylam intends to submit a New Drug Application (NDA) at the end of 2017 and a marketing authorization application in early 2018. The full results of the study will be presented at a European Congress in November.
Copyright (c) 2017 CercleFinance.com. All rights reserved.